It’s official. Regenerative medicine (RM) companies are surging during COVID-19.
There are now 800+ companies developing regenerative medicine products for therapeutic use in humans — hundreds of which are contributing toward the management of the global COVID-19 pandemic.
The rapid growth of RM companies is being driven by:
- Use of cell therapies in the treatment of COVID-19 complications, such as immune and respiratory complications
- Promise of MSCs for ameloriating COVID-induced respiratory distress, such as ARDS
- Accelerated pathways for regulatory approvals during COVID-19
- Increased interest among pharmaceutical companies in RM partnerships related to COVID-19
- Surging funding for RM therapies due to support from BARDA, CIRM, NIAID, and other groups
- Potential for RM therapies to support the management of the largest pandemic in modern history
Role of Regenerative Medicine in COVID-19
Since the outbreak of the new type of COVID-19 in December 2019, the scientific community has been working fervently to develop treatments to combat the disease. Globally, scientists are exploring every potential weapon to suppress the global threat.
Approaches under investigation include vaccines, medications, combination therapies, and perhaps most interestingly, regenerative therapies with promising cell types such as natural killer (NK) cells, dendritic cells, stem cells, exosomes, amniotic fluid and placental sourced components, and more.
In two notable examples, stem cell companies Mesoblast and Atherys are enrolling for 300 patient and 400 patient trials, respectively — two of the largest stem cell trials to date against COVID-19.
For a limited-time, you can claim the world’s only searchable, sortable database of regenerative medicine companies that is continuously updated for 50% off — only $97.
Imagine having instant access to all known regenerative medicine (RM) companies worldwide, without sacrificing weeks of unncessary research or being at risk of missing critical opportunities for…
- R&D collaborations
- Manufacturing partnerships
- In-licensing deals
- Supply chain opportunities
- M&A opportunities
- And more
Act now to claim the “Global Regenerative Medicine (RM) Industry Database 2020” for 50% off—before it expires.
What questions do you have about the role of regenerative medicine in the global COVID-19 pandemic? Ask them in the comments below.